Miach Orthopaedics, Inc., a company transforming the treatment of anterior cruciate ligament (ACL) tears from reconstruction to restoration with the Bridge-Enhanced ACL. Restoration (BEAR®) Implant, announced Jamal Rushdy has been selected as the...
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Tranexamic Acid in 0.7% Sodium Chloride Injection in the United States. The product contains the same active ingredient as...
Women's health supplement brand Ritual in partnership with Brooklyn College (CUNY) announced the publication of the folate results from their clinical trial on their top-selling Essential Prenatal in the journal Frontiers in Nutrition. The...
Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, announced today a partnership with Elaaj Bio, a biotechnology company focused on development...
BioOra Limited, a New Zealand-based company pioneering automated, cost-effective CAR T-cell manufacturing, announced the signing of a binding Heads of Terms agreement with Wellingto. Zhaotai Therapies Limited (Wellington Zhaotai) under which...
NurtureBio, a new maternal and child wellness company focused on emerging scientific solutions to gut health issues, today announced its official launch and the release of its first product: a synbiotic supplement. This synbiotic features human...
2nd Annual MaxPotent Pharma Summit – a leading international platform bringing together senior executives, regulatory authorities, technology providers, and pharmaceutical innovators dedicated to advancing the future of Highly Potent Active...
Novo Nordisk announced that starting Monday, May 4, Ozempic® (semaglutide) tablets 1.5 mg, 4 mg, and 9 mg will be available for adults with type 2 diabetes in the US. Ozempic® is the only FDA-approved oral peptide GLP-1 medication for adults with...
Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who...
YARAL Pharma Inc. the rapidly growing U.S. generics subsidiary of IBSA (Institut Biochimique SA), announced that its Diclofenac Epolamine Topical System 1.3%, the authorized generic of Flector® (diclofenac epolamine) topical system 1.3%, is now...
SQ Innovation, developer of Lasix® ONYU, announced two important regulatory milestones in its international expansion strategy: the receipt of a CE marking certificate for the Lasix ONYU device, and the acceptance of Lasix ONYU by the European...
Rapid Nexus Nanotech Wound Solutions, Inc., a California-based medical technology company, announced it has secured supply contracts with the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) and will begin commercial...
AbbVie announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® (risankizumab-rzaa) for subcutaneous (SC) induction for the treatment of adult patients with moderately to severely...
Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced the receipt of U.S. Food and Drug Administration (FDA) clearance to initiate CK0801 Phase 2...
Merck known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) approved IDVYNSO™, a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir, for the treatment of HIV-1...
Orthogon Therapeutics announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first-in-class drug against BK polyomavirus. BK virus...
Avantor, Inc. a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced the expansion of its North American quality control capabilities with the addition of...
A team led by principal investigators Bobo Dang and Ting Zhou at Westlake University/Westlake Laboratory reported in Science a high-throughput platform for engineering fast-acting covalent protein therapeutics. Their work, titled "A...
CellCentric, a clinical-stage biotechnology company developing inobrodib as a first-in-a-class, oral p300/CBP inhibitor for the treatment of multiple myeloma, announced the initiation of DOMMINO-1, a pivotal Phase 2 clinical trial evaluating...
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh...
